Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 13/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283169 | 0.85 | SMO (0.43) | CYP11B1CYP11B2SMONR3C1MAPK1 | |
| SCHEMBL27704046 | 0.81 | NR3C1 (0.44) | CYP11B1CYP11B2SMONR3C1CYP3A4 | |
| SCHEMBL27724689 | 0.80 | NR3C1 (0.53) | SMONR3C1 | |
| SCHEMBL4281989 | 0.80 | NR3C1 (0.47) | CYP11B1CYP11B2SMONR3C1 | |
| SCHEMBL4280388 | 0.75 | NR3C1 (0.62) | CYP11B1CYP11B2NR3C1 | |
| SCHEMBL4273934 | 0.75 | NR3C1 (0.61) | CYP11B1CYP11B2SMONR3C1 | |
| SCHEMBL4286606 | 0.74 | NR3C1 (0.43) | CYP11B1CYP11B2SMONR3C1MAPK1 | |
| SCHEMBL4277596 | 0.74 | NR3C1 (0.57) | CYP11B1CYP11B2NR3C1CYP3A4TSHR | |
| SCHEMBL4276180 | 0.74 | NR3C1 (0.68) | SMONR3C1 | |
| SCHEMBL27724553 | 0.73 | CYP11B1 (0.54) | CYP11B1CYP11B2SMONR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893588-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2008-03-05 | — | — | EP | claimed |
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | claimed |
| WO-2006135826-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-21 | — | — | WO | claimed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622594-B2 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060633-A1 | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, MC2R, NR3C2 | CYP11B1 24/4885CYP11B2 40/4885SMO 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.